603669 Lionco Pharmaceutical Group
- 4.49
- +0.21+4.91%
Lionco Pharmaceutical Group News
Lionco Pharmaceutical Gets Nod to Amend Cefuroxime Sodium for Injection's Production Standards
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Lionco Pharmaceutical Group (603669.SH): net loss of 40.4002 million yuan in the first half of the year.
On August 23, Gelonhui reported the semi-annual report for the year 2024, with revenue of 0.141 billion yuan, a year-on-year increase of 25.29%; net income attributable to shareholders of the listed company was -40.4002 million yuan.
Lionco Pharmaceutical Group (603669.SH): Subsidiary Cefoperazone Sodium for Injection passes the generic drug consistency evaluation.
On August 14, Gelonhui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. (referred to as Lionco Pharmaceutical), recently received the approval notice of the supplementary drug application for the injection of cefoperazone sodium (referred to as the pharmaceutical) issued by the State Administration of Drug Administration. The pharmaceutical has passed the consistency evaluation of generic drug quality and efficacy. Cefoperazone sodium for injection is mainly used for: lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, and meningitis caused by pneumococcus or influenza bacillus.
Lionco Pharmaceutical's Unit to Trial Esomeprazole Magnesium Sodium Bicarbonate Dry Suspension
Lionco Pharmaceutical Group (603669.SH): Its subsidiary has obtained a notice of approval for clinical trials of drugs.
On July 17, Grail Street reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "Lionco Pharmaceutical") recently obtained the Drug Clinical Trial Approval Notice for esomeprazole magnesium and sodium bicarbonate dry mixed suspension (I) issued by the Drug Evaluation Center (CDE) of the National Drug Administration. Esomeprazole magnesium and sodium bicarbonate dry mixed suspension (I) is clinically intended for the prevention of the recurrence of gastroesophageal reflux disease (GERD) symptoms in patients with cured esophagitis - long-term treatment and GERD symptom control; which requires continuous treatment.
Lionco Pharmaceutical Group (603669.SH): Clinical trial of esomeprazole magnesium and sodium bicarbonate dry mixed suspension (Ⅰ) approved.
Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd., recently obtained...
Lionco Pharma Ties Up With Laboratoire Bailly-Creat on International Sales
Lionco Pharmaceutical Group (603669.SH): signed a strategic cooperation framework agreement with Laboratoire Bailly-Creat.
On July 15th, Gelonhui reported that Lionco Pharmaceutical Group (603669.SH) has recently signed a strategic cooperation framework agreement with Laboratoire Bailly-Creat (hereinafter referred to as the "Party B"). In recent years, due to the decline in sales of the company's main products, the existing production lines of Hainan Lionco Pharmaceutical Co., Ltd., including lyophilized powder injection workshops, cephalosporin powder injection workshops, powder injection workshops, and small-capacity preparation workshops, have a low utilization rate. Hainan Lionco Pharmaceutical Co., Ltd. will fully leverage its production capacity advantages to ensure the company's normal production and supply of products, while actively seeking CMO and...
2024 Interim Performance Forecast
China Accepts Lionco Pharmaceutical Group Subsidiary's Supplementary Application for Alanyl Glutamine Injection
Lionco Pharmaceutical Group (603669.SH): its subsidiary, Acetylcysteine-Taurine Injection, has obtained approval for new specifications.
On July 3, Greater Pharma announced that its subsidiary, Hainan Lionco Pharmaceutical Group, received approval from the National Medical Products Administration for the supplemental application of the drug Acetylcysteine Injection. Lionco applied for a new Acetylcysteine Injection specification (50ml: 10g) which has been approved. Acetylcysteine Injection is indicated for patients who need to supplement glutamine in parenteral nutrition, including those in a state of catabolic metabolism and hypermetabolism.
Is Lionco Pharmaceutical GroupLtd (SHSE:603669) Using Too Much Debt?
Lingkang Pharmaceutical (603669.SH): Plans to terminate the “Hainan Lingkang Pharmaceutical Mei'an Production Base Construction Project (Phase I)”
Gelonghui, May 16, 丨 Lingkang Pharmaceutical (603669.SH) announced that the fund-raising investment project to be terminated is the “Hainan Lingkang Pharmaceutical Mei'an Production Base Construction Project (Phase I)”, with a total investment of 670,000 yuan and an investment of 525.00 million yuan using raised capital. The implementing entity of this project is Hainan Lingkang Pharmaceutical Co., Ltd., a subsidiary of the company. The implementation site is site B0615, Mei'an Technology New Town Phase 1, Haikou National High-tech Industrial Development Zone, Hainan Province. The amount of capital raised this time was 474.775,800 yuan (including accumulated interest on bank deposits received
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 26% Price Jump
Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 18% Last Week
Lingkang Pharmaceutical (603669.SH) released annual results, with a net loss of 151 million yuan to mother, a year-on-year decrease of 22.65%
According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) released its 2023 annual report. The group achieved operating income of 197 million yuan, a year-on-year decrease of 31.95%; achieved a net loss attributable to shareholders of listed companies of 151 million yuan, a year-on-year narrowing of 22.65%; realized a net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 182 million yuan, a year-on-year decrease of 10.9%; a basic loss per share. The company is mainly engaged in R&D, production and sales of chemical prescription drugs. The company adheres to the market-based product development strategy. The product variety is rich, the structure is reasonable, and numerous
Lingkang Pharmaceutical (603669.SH) announced first-quarter results, with a net loss of 16.0415 million yuan
Lingkang Pharmaceutical (603669.SH) released its report for the first quarter of 2024. The group achieved operating revenue during the period...
Even After Rising 16% This Past Week, Lionco Pharmaceutical GroupLtd (SHSE:603669) Shareholders Are Still Down 44% Over the Past Three Years
Analysis
Price Target
No Data
